News FocusASIAN MEDICINE

The New Face of Traditional Chinese Medicine

Science  10 Jan 2003:
Vol. 299, Issue 5604, pp. 188-190
DOI: 10.1126/science.299.5604.188

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

TOKYO-- This year, the U.S. Food and Drug Administration approved a phase II trial to test the efficacy of Kanglaite in treating non-small-cell lung cancer, making Kanglaite the first drug derived from a traditional Chinese herbal remedy to go into clinical trials in the United States. Asian governments are hoping that high-volume screening and rigorous clinical trials will unlock the secrets of ancient herbal remedies--and that the results will pass muster with Western scientists.